1. Home
  2. HTLM vs SEPN Comparison

HTLM vs SEPN Comparison

Compare HTLM & SEPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HTLM
  • SEPN
  • Stock Information
  • Founded
  • HTLM 2014
  • SEPN 2022
  • Country
  • HTLM Singapore
  • SEPN United States
  • Employees
  • HTLM N/A
  • SEPN N/A
  • Industry
  • HTLM
  • SEPN
  • Sector
  • HTLM
  • SEPN
  • Exchange
  • HTLM NYSE
  • SEPN NYSE
  • Market Cap
  • HTLM 153.9M
  • SEPN 1.0B
  • IPO Year
  • HTLM 2024
  • SEPN 2024
  • Fundamental
  • Price
  • HTLM $9.65
  • SEPN $21.35
  • Analyst Decision
  • HTLM
  • SEPN Strong Buy
  • Analyst Count
  • HTLM 0
  • SEPN 4
  • Target Price
  • HTLM N/A
  • SEPN $43.67
  • AVG Volume (30 Days)
  • HTLM 162.9K
  • SEPN 482.6K
  • Earning Date
  • HTLM 02-15-2025
  • SEPN 02-15-2025
  • Dividend Yield
  • HTLM N/A
  • SEPN N/A
  • EPS Growth
  • HTLM N/A
  • SEPN N/A
  • EPS
  • HTLM N/A
  • SEPN N/A
  • Revenue
  • HTLM $4,563,246.00
  • SEPN $981,000.00
  • Revenue This Year
  • HTLM N/A
  • SEPN $406.62
  • Revenue Next Year
  • HTLM N/A
  • SEPN N/A
  • P/E Ratio
  • HTLM N/A
  • SEPN N/A
  • Revenue Growth
  • HTLM N/A
  • SEPN N/A
  • 52 Week Low
  • HTLM $2.57
  • SEPN $18.62
  • 52 Week High
  • HTLM $13.74
  • SEPN $28.99
  • Technical
  • Relative Strength Index (RSI)
  • HTLM N/A
  • SEPN N/A
  • Support Level
  • HTLM N/A
  • SEPN N/A
  • Resistance Level
  • HTLM N/A
  • SEPN N/A
  • Average True Range (ATR)
  • HTLM 0.00
  • SEPN 0.00
  • MACD
  • HTLM 0.00
  • SEPN 0.00
  • Stochastic Oscillator
  • HTLM 0.00
  • SEPN 0.00

About HTLM HOMESTOLIFE LTD

Homestolife Ltd is a home furniture retailers that offers and sells customized furniture solutions in Singapore. It has six retail store locations that sell furniture manufactured from China and other Asian countries.

About SEPN SEPTERNA INC

Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, and GLP-1R, GIPR, GCGR.

Share on Social Networks: